Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Reasonable nutrient intake encompassing macronutrients and micronutrients have an independent protective relationship with NAFLD.
Why it matters
This review is about preventing nonalcoholic fatty liver disease, not Alzheimer's disease. It reports that nutrients, dietary strategies such as the Mediterranean diet, exercise, healthy lifestyle habits and environment may help prevent NAFLD.
-
The proportion of palliative utilization in cancer deaths started at 21.7% in 2010 and increased to 63.2% by 2020 with the beta coefficient of 0.09 (95% CI: 0.09-0.09).
Why it matters
This population study in Taiwan found that palliative care use rose for both cancer and non-cancer decedents, but non-cancer decedents were much less likely to receive it. It does not test any treatment, cure or prevention.
-
Up to 60% of people living with dementia who reside in care homes will ‘wander’ at some point.
Why it matters
This qualitative interview study of 19 care home staff suggests that person-centred care, positive risk taking and clear leadership may help support safe wandering in residents with dementia. It does not test any treatment, cure or prevention of Alzheimer's disease.
-
Of 563 articles retrieved, 12 met eligibility criteria.
Why it matters
This scoping review of 12 studies found that Alzheimer's disease and related dementias remain underdiagnosed in U.S. primary care, especially at the mild cognitive impairment stage, due to barriers at individual, interpersonal, and health system levels. It identifies where future research and intervention are needed but does not test ways to improve diagnosis.
-
Levels of underdiagnosis varied between 16% for stroke and 69% for prostate cancer in 2018.
Why it matters
This modelling study estimated how often several diseases go undiagnosed in England and where underdiagnosis occurs. It does not test any treatment, cure, or prevention for Alzheimer's disease.
-
42/100
There has been growing interest in the role of biofluid biomarkers to aid the diagnosis of dementia in older people.
Why it matters
This review found that neurofilament light chain has very high sensitivity and specificity in distinguishing young-onset dementia from primary psychiatric disorders. It suggests potential for a blood test to aid diagnosis, but further research is required and it does not report any treatment, cure, or prevention.
-
Higher socioeconomic status and increased frequency of physical activity were associated with a lower risk of both EOD and LOD.
Why it matters
This case-control study using Korean national health insurance data found that higher socioeconomic status and more frequent physical activity were associated with lower risk of both early- and late-onset dementia. Rural residence, heavy alcohol consumption, and higher fasting blood sugar levels were associated with increased risk of late-onset dementia but not early-onset dementia, and overall these factors impacted late-onset dementia more strongly.
-
The analysis revealed five distinct themes: (1) impact of the program, (2) facilitators enhancing participation, (3) barriers hindering participation, (4) suggestions for improving participation and (5) challenges to adopt digital platforms.
Why it matters
This qualitative study found that older adults with cognitive frailty and their caregivers reported a positive experience with the AGELESS multidomain program and preferred in-person sessions. It reports participant views on the program rather than measuring whether it prevents or treats Alzheimer's.
-
A total of 3777 studies were identified, and 106 studies met the inclusion criteria.
Why it matters
This scoping review examined injury prevention practices for runners, finding that supervision and individualized approaches are important. It contains no information on Alzheimer's disease.
-
42/100
Microstructural alterations in brain tissue play a crucial role in the pathophysiology of frontotemporal dementia (FTD).
Why it matters
Using NODDI diffusion MRI, this study found widespread white matter changes across frontotemporal dementia variants and grey matter changes in specific regions, and built an exploratory machine-learning model to classify subtypes. It is about imaging characterization and classification, not about treating, curing or preventing the disease.
-
Differences in system‐level factors such as access to dementia specialists is a contributing factor to differences in diagnosis rates in MA and TM.
Why it matters
Among a matched sample of over 15 million beneficiaries, the incident dementia diagnosis rate was 0.11 percentage points lower for Medicare Advantage beneficiaries than for traditional Medicare beneficiaries seen by the same primary care provider. Medicare Advantage patients were also less likely to be seen by dementia specialists.
-
A total of 2301 patients completed an intake from January 2023 to March 2024.
Why it matters
This study describes a virtual-first behavioral health care model for older adults with serious mental illness, substance use disorders, and dementia, finding high rates of housing and food insecurity. It does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Typical normative models appear appropriate for remote self‐administered measures and are sensitive to cognitive impairment.
Why it matters
This study developed normative data for remote self-administered cognitive tests through Mayo Test Drive for adults ages 33 to 100. The base model adjusted for age, age2, sex and education, and no additional terms including device type or area deprivation index met the cutoff for inclusion.
-
42/100
Alzheimer's disease and related diseases (ADRD) is a progressive and inexorable disease.
Why it matters
This study analyzed the consequences of changes to antidementia drug reimbursement in France on healthcare use. It found increases in private neurologist or psychiatrist consultations and exposure to recommended drugs after the reimbursement withdrawal, contrary to fears expressed, but does not test any treatment, cure, or prevention.
-
Air pollution is the greatest environmental threat to human health in the world today and is responsible for an estimated 7-9 million deaths annually.
Why it matters
Using EPA modelling software, this study estimated that fine-particle air pollution (PM2.5) in Texas in 2016 was linked to about 8,405 premature deaths and 24,575 new cases of Alzheimer's disease, even though most of the state met the EPA's 12 μg/m3 standard; 98.9% of Texans lived where levels exceeded the WHO's 5 μg/m3 recommendation. These figures are calculated from assumed pollution–disease relationships, not counted in patients, so they do not show that pollution causes Alzheimer's or that cleaner air would prevent it.
-
Early-diagnosed patients (N = 421) have a lower utilization rate of inpatient skilled nursing facility, nursing home and hospitalization than late-diagnosed patients (N = 2817) after being diagnosed with AD.
Why it matters
This study compared patients diagnosed with Alzheimer's disease early versus late and found early-diagnosed patients had lower use of nursing homes and hospitals and some medical cost savings. It suggests earlier diagnosis may bring long-term healthcare savings, but it does not test whether earlier diagnosis changes the course of the disease, and the authors say further research is needed.
-
In the last decade, an important effort was made in the field of Down syndrome to find new interventions that improve cognition.
Why it matters
This review notes that translating findings from Down syndrome research into effective cognitive therapies has been disappointingly slow and has often failed in clinical trials. It calls for biomarker-based decision-making and preventive, multimodal approaches, but reports no therapy that has been shown to treat, cure or prevent Alzheimer's disease.
-
Although observational studies have identified modifiable risk factors for Alzheimer disease and related dementias (ADRD), randomized controlled trials (RCTs) of risk factor modification for ADRD prevention have been inconsistent or inconclusive.
Why it matters
This paper discusses why randomized controlled trials of risk factor modification for Alzheimer's disease prevention have been inconsistent or inconclusive despite observational findings. It argues that better use of observational data in designing trials may increase the likelihood of successful or at least definitive prevention trials.
-
42/100
Science journalist Charles Piller, working with neuroscientist Matthew Schrag and independent image-forensics experts, published a six-month investigation finding apparent digital manipulation (duplicated bands, spliced images) in Western blot figures from papers by Sylvain Lesné, including his highly influential 2006 Nature paper proposing that a specific amyloid protein (Aβ*56) causes memory loss.
Why it matters
Science journalist Charles Piller, working with neuroscientist Matthew Schrag and independent image-forensics experts, published a six-month investigation finding apparent digital manipulation (duplicated bands, spliced images) in Western blot figures from papers by Sylvain Lesné, including his highly influential 2006 Nature paper proposing that a specific amyloid protein (Aβ*56) causes memory loss. The report noted that, 15 years on, few other labs had been able to detect Aβ*56 in human tissue at all.
-
42/100
This study aims to analyze the relationship between cognitive function and out-of-pocket cost of the state change of multiple chronic conditions in individuals aged 60 or older.
Why it matters
This study examined how changes in multiple chronic conditions relate to out-of-pocket medical costs among older adults in South Korea, including those with cognitive decline. It found higher costs among those with cognitive decline, which is about financial burden rather than treating or curing Alzheimer's disease.
-
Many rural American Indian and Alaska Native (AIAN) veterans receive care from the Indian Health Service (IHS).
Why it matters
In this study, American Indian and Alaska Native veterans using Indian Health Service care had lower odds of all-cause dementia than non-veterans, but the study did not test any treatment or prevention. It only describes health status, service use, and cost, so it does not show how to treat, cure, or prevent Alzheimer's disease.
-
Emerging evidence suggests that some of these effects are similar to those seen in adults with symptoms of mild cognitive impairment (MCI) in the early stages of dementia, including impaired concentration, orientation, acquisition of recent memories (anterograde amnesia), recall of past memories (retrograde amnesia), social functioning, and self-care.
Why it matters
The authors predict that rates of Alzheimer's disease and related dementias will rise four-to-six-fold from 2060 to 2100, far above CDC projections, based on the idea that excessive screen time during brain development causes effects similar to mild cognitive impairment. This is a prediction, not a tested finding, and it offers no treatment, cure or prevention.
-
Nearly half of the incident ADRD codes were associated with a hospital‐based encounter.
Why it matters
In an integrated health system, 25,278 first dementia diagnoses were recorded, slightly more than half in ambulatory care and the rest during hospital encounters, with no racial/ethnic or language differences in the clinic-diagnosed group. This describes where and how diagnoses are made, not how the disease is treated, cured or prevented.
-
Eighty-three theoretical or research articles from 1981 to 2020 were identified.
Why it matters
This concept analysis examined elderspeak, an inappropriate simplified speech register used with older adults, and found that exaggerated prosody reduced comprehension. It concerns communication with older adults, not Alzheimer's disease treatment, cure or prevention.
-
Parkinson's disease (PD) is characterized by degeneration of dopaminergic neurons in the substantia nigra pars compacta and other neuronal populations.
Why it matters
This review discusses medical and surgical treatments for Parkinson's disease, including dementia as one non-motor symptom treated with acetylcholinesterase inhibitors. It is about Parkinson's disease management, not about treating, curing or preventing Alzheimer's disease.
From across this topic
10 of the 7,967 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- PRagmatic trial Of Video Education in Nursing homes: The design and rationale for a pragmatic cluster randomized trial in the nursing home setting
- Using Health Utility Index (HUI) for measuring the impact on health-related quality of Life (HRQL) among individuals with chronic diseases
- Α Virtual Reality App for Physical and Cognitive Training of Older People With Mild Cognitive Impairment: Mixed Methods Feasibility Study
- Alone in the Mind: Review of Research Examining the Link Between Loneliness and Dementia
- Asian Americans & Racism: Individual and Structural Experiences (ARISE) Pilot Study: Cultural and Linguistic Considerations in Studying Chinese, Vietnamese, and Korean American Older Adults
- Cognability: An Ecological Theory of neighborhoods and cognitive aging
- The role of nutrition and the Mediterranean diet on the trajectories of cognitive decline
- Long-term prognosis after lacunar infarction
- Can brain exercises mitigate cognitive decline? A quasi-experimental evaluation of the StrongerMemory program
- When does brain aging accelerate? Dangers of quadratic fits in cross-sectional studies